Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mangoceuticals, Inc. ( (MGRX) ) just unveiled an announcement.
On November 13, 2025, Mangoceuticals, Inc. announced a partnership with Eli Lilly and Novo Nordisk to provide affordable access to Zepbound and Wegovy for obesity management. This initiative, which includes the launch of MangoRx Direct and PeachesRx Direct programs, aims to offer direct access to these medications through a secure telehealth platform, providing virtual consultations and personalized treatment plans. The partnership aligns with recent government efforts to reduce the cost of GLP-1 medications and addresses the significant impact of obesity on the U.S. healthcare system.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc. is a company that focuses on developing, marketing, and selling a variety of health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx. The company is involved in men’s wellness telemedicine services and products, particularly in areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management.
Average Trading Volume: 238,445
Technical Sentiment Signal: Sell
Current Market Cap: $18.54M
Learn more about MGRX stock on TipRanks’ Stock Analysis page.